The new report* studies the adverse impact on professional opinion caused by two academic studies, and depicts the risk that healthcare products face as a result of constant developments and investigations in the field.
Vertebral Compression Fractures (VCFs) can be treated using vertebral augmentation devices, also known as balloon kyphoplasty devices, and vertebroplasty devices. Both offer non-surgical treatment in outpatient settings, when conventional therapies such as rest, back bracing or drug-based therapies have not been effective, before physicians resort to invasive and expensive operations.
However, in August 2009, two studies were published in the New England Journal of Medicine (NEJM) questioning the benefits provided by vertebroplasty and vertebral augmentation procedures. These studies led physicians to favour alternative treatment options for VCFs, and prompted the American Association of Orthopedic Surgeons (AAOS) to strongly recommend against the use of vertebroplasty for VCF treatment. This in turn led some private insurers in the US to roll back their coverage policies for these procedures. The availability of reimbursements for vertebral augmentation procedures dramatically affects this medical market, as vertebral augmentation and vertebroplasty procedures are comparatively expensive to undertake.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/
These events crippled growth in the kyphoplasty and vertebroplasty market during 2009 and 2010, but the markets are now recovering from this damage. Growing doubts among physicians and specialists concerning the sample patient population considered by the two studies led to a number of new studies being published, which supported vertebroplasty and kyphoplasty procedures. Consequent recommendations from organizations such as the International Osteoporosis Foundation and Society of Interventional Radiology for the treatments helped in alleviating the bad press which kyphoplasty and vertebroplasty procedures had been given, and the market has shown a gradual recovery from 2010 onwards.
This case depicts the vital importance of clinical studies and academic research in the medical industry, as new findings can often not only help, but sometimes hinder, existing treatment options.
This report gives an overview of vertebral compression fracture, treatment modalities and major vertebral compression fracture treatment segments. Key segments covered include vertebral augmentation devices (referred as balloon kyphoplasty devices in some places) and vertebroplasty devices. The report also gives annualized market revenues data from 2004 to 2011, forecast forward for seven years to 2018, pipeline analysis split across different phases, and profiles of key products that are under clinical development.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/
Visit our report store: http://www.globaldata.com/
For more details contact:
pressreleases@
North America: +1 646 395 5477
Europe:
Asia Pacific:
